Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Apellis Pharmaceuticals (APLS) Leases (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Leases readings, the most recent being $18.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Leases rose 13.13% year-over-year to $18.2 million, compared with a TTM value of $18.2 million through Dec 2025, up 13.13%, and an annual FY2025 reading of $18.2 million, up 13.13% over the prior year.
  • Leases hit $18.2 million in Q4 2025 for Apellis Pharmaceuticals, down from $19.7 million in the prior quarter.
  • The five-year high for Leases was $22.5 million in Q1 2021, with the low at $14.6 million in Q2 2025.
  • Median Leases over the past 5 years was $18.0 million (2023), compared with a mean of $18.2 million.
  • The sharpest move saw Leases soared 69.3% in 2021, then fell 20.68% in 2023.
  • Year by year, Leases stood at $19.9 million in 2021, then dropped by 5.8% to $18.7 million in 2022, then decreased by 10.68% to $16.7 million in 2023, then decreased by 3.95% to $16.1 million in 2024, then grew by 13.13% to $18.2 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $18.2 million, $19.7 million, and $14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.